IMCC (IM Cannabis) FCF Margin % : 19.30% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IM Cannabis FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. IM Cannabis's Free Cash Flow for the three months ended in Sep. 2024 was $1.98 Mil. IM Cannabis's Revenue for the three months ended in Sep. 2024 was $10.25 Mil. Therefore, IM Cannabis's FCF Margin % for the quarter that ended in Sep. 2024 was 19.30%.

As of today, IM Cannabis's current FCF Yield % is -16.76%.

The historical rank and industry rank for IM Cannabis's FCF Margin % or its related term are showing as below:

IMCC' s FCF Margin % Range Over the Past 10 Years
Min: -114.43 Med: -26.14 Max: 5.33
Current: -1.95

During the past 13 years, the highest FCF Margin % of IM Cannabis was 5.33%. The lowest was -114.43%. And the median was -26.14%.

IMCC's FCF Margin % is ranked better than
62.14% of 980 companies
in the Drug Manufacturers industry
Industry Median: 0.87 vs IMCC: -1.95

IM Cannabis FCF Margin % Historical Data

The historical data trend for IM Cannabis's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IM Cannabis FCF Margin % Chart

IM Cannabis Annual Data

Trend

Apr13

Apr14

Apr16

Apr17

Apr18

Apr19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-66.89

-114.43

-26.14

-17.74

IM Cannabis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															43.29	-2.29	-5.23	6.42	19.30

Competitive Comparison of IM Cannabis's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, IM Cannabis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IM Cannabis's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IM Cannabis's FCF Margin % distribution charts can be found below:

* The bar in red indicates where IM Cannabis's FCF Margin % falls into.

Save Embed

;

Save Embed

;

IM Cannabis FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

IM Cannabis's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-6.452	/	36.377
	=	-17.74 %

IM Cannabis's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	1.978	/	10.249
	=	19.30 %

IM Cannabis FCF Margin % Related Terms

Thank you for viewing the detailed overview of IM Cannabis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IM Cannabis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IM Cannabis Corp (NAS:IMCC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IMCC:Canada

Address

Central District, Kibbutz Glil Yam, ISR, 4690500

Website

https://www.imcannabis.com

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.